Cost of cardiovascular disease prevention: towards economic evaluations in prevention programs.
作者信息
Santos João Vasco, Vandenberghe Désirée, Lobo Mariana, Freitas Alberto
机构信息
Public Health Unit, ACES Grande Porto VIII - Espinho/Gaia, ARS Norte, Portugal.
MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Portugal.
出版信息
Ann Transl Med. 2020 Apr;8(7):512. doi: 10.21037/atm.2020.01.20.
Abstract
摘要
相似文献
1
Cost of cardiovascular disease prevention: towards economic evaluations in prevention programs.心血管疾病预防的成本：迈向预防项目的经济评估
Ann Transl Med. 2020 Apr;8(7):512. doi: 10.21037/atm.2020.01.20.
2
Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.针对孕妇戒烟及预防复吸项目的经济学评估：一项系统综述
Value Health. 2008 Mar-Apr;11(2):180-90. doi: 10.1111/j.1524-4733.2007.00239.x. Epub 2007 Sep 13.
3
Economic Evaluations of Falls Prevention Programs for Older Adults: A Systematic Review.老年人跌倒预防计划的经济评价：系统评价。
J Am Geriatr Soc. 2018 Nov;66(11):2197-2204. doi: 10.1111/jgs.15578. Epub 2018 Oct 16.
4
CARDIOVASCULAR SCREENING OF YOUNG ATHLETES: A REVIEW OF ECONOMIC EVALUATIONS.青少年运动员心血管筛查的经济学评价综述
Int J Technol Assess Health Care. 2017 Jan;33(1):76-83. doi: 10.1017/S0266462317000162. Epub 2017 Apr 24.
5
An Economic Evaluation of a Comprehensive School-Based Caries Prevention Program.一项基于学校的综合性龋齿预防项目的经济评估。
JDR Clin Trans Res. 2019 Oct;4(4):378-387. doi: 10.1177/2380084419837587. Epub 2019 Apr 22.
6
Economic evaluations of screening programs: a review of methods and results.筛查项目的经济学评估：方法与结果综述
Clin Chim Acta. 2002 Jan;315(1-2):31-40. doi: 10.1016/s0009-8981(01)00718-5.
7
Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.他汀类药物在心血管疾病一级预防中的成本效益：比利时的系统评价与经济分析
Acta Cardiol. 2009 Feb;64(1):1-10. doi: 10.2143/AC.64.1.2034354.
8
Economic evaluations of public health implementation-interventions: a systematic review and guideline for practice.公共卫生实施干预措施的经济评价：系统评价与实践指南。
Public Health. 2019 Apr;169:101-113. doi: 10.1016/j.puhe.2019.01.012. Epub 2019 Mar 13.
9
Economic evaluations and their use in infection prevention and control: a narrative review.经济评估及其在感染预防和控制中的应用：叙述性综述。
Antimicrob Resist Infect Control. 2018 Feb 27;7:31. doi: 10.1186/s13756-018-0327-z. eCollection 2018.
10
Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions.肺炎球菌疾病：卫生效用、资源利用、成本及干预措施经济评价的系统综述。
Value Health. 2019 Nov;22(11):1329-1344. doi: 10.1016/j.jval.2019.06.011. Epub 2019 Sep 10.
引用本文的文献
1
Direct economic burden of acute coronary syndromes in the Portuguese National Health Service-facts and trends between 2002 and 2022.葡萄牙国家医疗服务体系中急性冠脉综合征的直接经济负担——2002年至2022年的事实与趋势
Front Public Health. 2025 Mar 18;13:1433307. doi: 10.3389/fpubh.2025.1433307. eCollection 2025.
2
Machine learning-based risk prediction for major adverse cardiovascular events in a Brazilian hospital: Development, external validation, and interpretability.基于机器学习的巴西医院主要不良心血管事件风险预测：开发、外部验证和可解释性。
PLoS One. 2024 Oct 11;19(10):e0311719. doi: 10.1371/journal.pone.0311719. eCollection 2024.
3
Optimizing cardiovascular disease mortality prediction: a super learner approach in the tehran lipid and glucose study.优化心血管疾病死亡率预测：特兰脂质和血糖研究中的超级学习者方法。
BMC Med Inform Decis Mak. 2024 Apr 16;24(1):97. doi: 10.1186/s12911-024-02489-0.
4
Postprandial Plasma Glucose Measured from Blood Taken between 4 and 7.9 h Is Positively Associated with Mortality from Hypertension and Cardiovascular Disease.在4至7.9小时之间采集的血液所测得的餐后血浆葡萄糖与高血压和心血管疾病导致的死亡率呈正相关。
J Cardiovasc Dev Dis. 2024 Feb 4;11(2):53. doi: 10.3390/jcdd11020053.
5
Optimizing Cardiac Wireless Implant Communication: A Feasibility Study on Selecting the Frequency and Matching Medium.优化心脏无线植入物通信：选择频率和匹配介质的可行性研究。
Sensors (Basel). 2023 Mar 24;23(7):3411. doi: 10.3390/s23073411.
6
Why and How Should We Assess the Cardiovascular Risk in Patients with Juvenile Idiopathic Arthritis? A Single-Centre Experience with Carotid Intima-Media Measurements.为什么以及如何评估青少年特发性关节炎患者的心血管风险？一项关于颈动脉内膜中层测量的单中心经验。
Children (Basel). 2023 Feb 22;10(3):422. doi: 10.3390/children10030422.
7
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.在葡萄牙心血管和脑血管疾病二级预防中，与单一成分药物分别使用相比，CNIC复方药丸策略的成本效益：MERCURY研究
J Health Econ Outcomes Res. 2022 Nov 22;9(2):134-146. doi: 10.36469/001c.39768. eCollection 2022.
8
Reduction in medical costs for cardiovascular diseases through innovative health awareness projects in a rural area in Japan.通过在日本农村地区开展创新的健康意识项目来降低心血管疾病的医疗费用。
PLoS One. 2022 Nov 16;17(11):e0277600. doi: 10.1371/journal.pone.0277600. eCollection 2022.
9
Cerebrovascular development: mechanisms and experimental approaches.脑血管发育：机制与实验方法。
Cell Mol Life Sci. 2021 May;78(9):4377-4398. doi: 10.1007/s00018-021-03790-1. Epub 2021 Mar 10.
本文引用的文献
1
The financial burden of non-communicable diseases in the European Union: a systematic review.欧盟非传染性疾病的财政负担：系统综述。
Eur J Public Health. 2020 Aug 1;30(4):833-839. doi: 10.1093/eurpub/ckz073.
2
5-year versus risk-category-specific screening intervals for cardiovascular disease prevention: a cohort study.5 年与基于风险类别的特定心血管疾病预防筛查间隔：队列研究。
Lancet Public Health. 2019 Apr;4(4):e189-e199. doi: 10.1016/S2468-2667(19)30023-4.
3
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家按年龄、性别和死因分类的死亡率，195 个国家和地区，1980-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
4
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、地区和国家残疾调整生命年（DALYs）359 种疾病和伤害以及 195 个国家和地区 1990-2017 年的健康期望寿命（HALE）：2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3.
5
Multimorbidity Trends in United States Adults, 1988-2014.美国人多种疾病患病趋势，1988-2014 年。
J Am Board Fam Med. 2018 Jul-Aug;31(4):503-513. doi: 10.3122/jabfm.2018.04.180008.
6
Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations.低收入和中等收入国家心血管疾病的一级和二级预防干预措施：经济评估的系统评价
Cost Eff Resour Alloc. 2018 Jun 14;16:22. doi: 10.1186/s12962-018-0108-9. eCollection 2018.
7
A cost-effectiveness analysis of a community based CVD program in Sweden based on a retrospective register cohort.基于回顾性登记队列的瑞典社区 CVD 项目的成本效益分析。
BMC Public Health. 2018 Apr 4;18(1):452. doi: 10.1186/s12889-018-5339-3.
8
10-Year Resource Utilization and Costs for Cardiovascular Care.心血管护理的 10 年资源利用与成本
J Am Coll Cardiol. 2018 Mar 13;71(10):1078-1089. doi: 10.1016/j.jacc.2017.12.064.
9
The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.非传染性疾病对医疗支出和国民收入的全球影响：系统评价。
Eur J Epidemiol. 2015 Apr;30(4):251-77. doi: 10.1007/s10654-014-9984-2. Epub 2015 Jan 18.
10
Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.谁需要实验室检查，谁需要他汀类药物？：基于非实验室检查、基于实验室检查以及分阶段的原发性心血管疾病筛查指南的比较与成本效益分析。
Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):25-32. doi: 10.1161/CIRCOUTCOMES.113.000397. Epub 2014 Jan 14.
Zotero 插件